Physiological Perspectives on the Use of Triheptanoin as Anaplerotic Therapy for Long Chain Fatty Acid Oxidation Disorders

MLA

Evgenia Sklirou, et al. “Physiological Perspectives on the Use of Triheptanoin as Anaplerotic Therapy for Long Chain Fatty Acid Oxidation Disorders.” Frontiers in Genetics, vol. 11, Jan. 2021. EBSCOhost, https://doi.org/10.3389/fgene.2020.598760.

APA

Evgenia Sklirou, Ahmad N. Alodaib, Steven F. Dobrowolski, Al-Walid A. Mohsen, & Jerry Vockley. (2021). Physiological Perspectives on the Use of Triheptanoin as Anaplerotic Therapy for Long Chain Fatty Acid Oxidation Disorders. Frontiers in Genetics, 11. https://doi.org/10.3389/fgene.2020.598760

Chicago

Evgenia Sklirou, Ahmad N. Alodaib, Steven F. Dobrowolski, Al-Walid A. Mohsen, and Jerry Vockley. 2021. “Physiological Perspectives on the Use of Triheptanoin as Anaplerotic Therapy for Long Chain Fatty Acid Oxidation Disorders.” Frontiers in Genetics 11 (January). doi:10.3389/fgene.2020.598760.